313 related articles for article (PubMed ID: 12481149)
21. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
[TBL] [Abstract][Full Text] [Related]
22. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
Krause MW; Raja R; Agarwal A; Silver MR; Scarlata D; Sciarra A; Kewalramani R
Drugs Aging; 2009; 26(8):665-75. PubMed ID: 19685932
[TBL] [Abstract][Full Text] [Related]
23. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
Hörl WH; Holzer H; Mayer GJ;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
[TBL] [Abstract][Full Text] [Related]
25. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
[TBL] [Abstract][Full Text] [Related]
26. [Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period].
Wanic-Kossowska M; Tykarski A; Kobelski M; Czekalski S
Pol Arch Med Wewn; 2006 Jul; 116(1):663-70. PubMed ID: 17340973
[TBL] [Abstract][Full Text] [Related]
27. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.
Warady BA; Arar MY; Lerner G; Nakanishi AM; Stehman-Breen C
Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235
[TBL] [Abstract][Full Text] [Related]
28. Darbepoetin alfa: a new therapy for the management of anaemia associated with chronic kidney disease.
Lindberg J
Expert Opin Biol Ther; 2002 Dec; 2(8):977-84. PubMed ID: 12517275
[TBL] [Abstract][Full Text] [Related]
29. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
31. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
Li WY; Chu TS; Huang JW; Wu MS; Wu KD
J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
[TBL] [Abstract][Full Text] [Related]
32. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
33. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients.
Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B
Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720
[TBL] [Abstract][Full Text] [Related]
34. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
[TBL] [Abstract][Full Text] [Related]
35. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
[TBL] [Abstract][Full Text] [Related]
36. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients.
Theodoridis M; Passadakis P; Kriki P; Panagoutsos S; Yannatos E; Kantartzi K; Sivridis D; Vargemezis V
Perit Dial Int; 2005; 25(6):564-9. PubMed ID: 16411523
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
[TBL] [Abstract][Full Text] [Related]
38. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
Hudson JQ; Sameri RM
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
[TBL] [Abstract][Full Text] [Related]
39. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
40. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
